The targeted ASPYRE-Lung panel for non-small cell carcinoma covers 114 variants in 11 genes (<i>ALK, BRAF, EGFR, ERBB2, KRAS, RET, ROS1, MET & NTRK1/2/3</i>) to robustly inform clinical management. This evidence concerns the gene BRAF and non-small cell lung carcinoma.